Dexmedetomidine Combined With Lidocaine Infusion Affect PONV

NACompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

August 1, 2020

Study Completion Date

January 12, 2021

Conditions
LidocaineDexmedetomidineNausea and Vomiting, Postoperative
Interventions
DRUG

lidocaine and dexmedetomidine infusion

Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.

DRUG

Saline infusion

Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery

DRUG

Lidocaine infusion

patients received an IV bolus infusion of lidocaine (2%) 1.5 mg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg made up to 20ml and 20ml normal saline every hour until 30 min before the end of operation, respectively.

DRUG

Dexmedetomidine infusion

Patients received IV bolus infusion of dexmedetomidine 0.5 μg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4μg/kg made up to 20ml and 20ml normal saline every houruntil 30 min before the end of operation, respectively.

Trial Locations (1)

246000

Department of Anqing Hospital Anesthesiology, Anqing

All Listed Sponsors
lead

Anqing Municipal Hospital

OTHER

NCT03809923 - Dexmedetomidine Combined With Lidocaine Infusion Affect PONV | Biotech Hunter | Biotech Hunter